← Human Trials & Peer-Reviewed Studies
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy
Plain-language guide to PMID 16877955 (2006): placebo-controlled randomized controlled trial study of BNP (Nesiritide) in 945 patients.
Key Facts
- PMID
- 16877955
- Journal
- Journal of hypertension
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Olsen MH et al. (10 authors)
- DOI
- 10.1097/01.hjh.0000239288.10013.04
What This Study Did, in Plain Language
What Was Tested
Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.
N-terminal pro-brain natriuretic peptide (Nt-proBNP) and high-sensitivity C-reactive protein (hsCRP) are cardiovascular risk markers in various populations, but are not well examined in hypertension.
Who Took Part
According to the abstract, 945 patients were involved.
PubMed indexes the participants as middle-aged adults, older adults and people over 80, both men and women.
In 945 hypertensive patients from the LIFE study with electrocardiographic left ventricular (LV) hypertrophy, the researchers measured traditional cardiovascular risk factors including electrocardiography, morning UACR, hsCRP by immunoturbidimetry assay and Nt-proBNP by immunoassay after 2 weeks of placebo treatment.
During 55 months' follow-up 80 patients suffered a composite endpoint.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got BNP (Nesiritide) and who got the comparison, which limits bias.
Some patients received a placebo instead of BNP (Nesiritide), giving a reference point.
The methods mention a period of 2 weeks.
What Was Measured
PubMed files the paper under topics including Albumins, Antihypertensive Agents, Atenolol, Biomarkers, C-Reactive Protein, Cardiovascular Diseases and Confounding Factors, Epidemiologic.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of BNP (Nesiritide) in 945 patients over 2 weeks.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2006 (Journal of hypertension), a journal based in Netherlands.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.